2016, Cilt 14, Sayı 1, Sayfa(lar) 040-045 |
|
Holotranscobalamin Levels in Mid Vitamin B12 Values |
Aynur Kırbaş1, Medeni Arpa1, Medine Cumhur Cüre1, Hacer Bilgin Topaloğlu1, Ebru Yaprak1, Özgür Baykan2 |
1Recep Tayyip Erdoğan Üniversitesi Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, Rize, Türkiye 2Atatürk Devlet Hastanesi, Biyokimya, Balıkesir, Türkiye |
Keywords: Vitamin B12, holotranscobalamin, neurological disorder |
Objective: Vitamin B12 has important functions in the body. Its deficiency results in hematological and
neurological impairments. Unless the deficiency status treated on early stage this neurological
degenerations become permanent. Some studies have shown that the vitamin B12 levels persist
between reference ranges, even the deficiency occurs. In addition holotranscobalamin that is the active
form of vitamin B12 has been shown that can lead to early diagnosis. We aimed to reveal the relation
between them within the 100-300ng/L of total vitamin B12 levels by evaluating the holotranscobalamin.
Material and Method: Patients (n:449) were divided into two groups according to their levels of
vitamin B12 levels: group 1 (<189 ng/L); group 2 (>189ng/L). We used cut-off values 189 ng/mL for
vitamin B12 and 25,1 pmol/L for holotranscobalamin as deficiency indicators. Both analytes were
measured by Chemiluminesans Microparticule Immunassay (CMIA) method. The relation between two
vitamins was evaluated by Pearson corelation analysis method.
Results: There was a positive statistically significant correlation between vitamin B12 and
holotranscobalamin in our groups. (r=0,491, p<0.001 and r=0,271, p<0.001, respectively). By the way
it seems the relation power decreased while total vitamin B12 levels increased, especially in second
group that in reference ranges Holotranscobalamin levels were below cut-off value in 31,4% patients.
Discussion: Its shown that total vitamin B12 measurement isn't enough to diagnose deficiency,
esspecially in 100-300ng/L levels holotranscobalamin can assist for early diagnosis and lead to early
treatment that protect clinical impairments.
|
|
|